Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study "ARC"


Phase 4 Results N/A

Eligibility Criteria

Inclusion Criteria

- Patients with non-valvular atrial fibrillation requiring electrical cardioversion o Atrial fibrillation of unknown duration

Exclusion Criteria

- Patients requiring extended anticoagulation after cardioversion due to concomitant risk factors as defined by CHADS2 score ≥ 1
- Significant renal dysfunction (CrCl <15mL/min)
- Significant hepatic dysfunction (Childs-Pugh Class B or C)
- History of coagulopathy
- Active bleeding
- Hypersensitivity to Rivaroxaban
- Concomitant use of anticoagulants
- Concomitant use of potent CYP3A4/P-gp inhibitors or inducers
- Interventions requiring interruption of therapy
- Pregnancy
- Age <18 y/o
- History of GI Bleed